Claims
- 1. A method of reducing intraocular pressure comprising administering to a subject a pharmaceutical composition comprising an effective amount of a compound of Formula I, or a pharmaceutically-acceptable salt thereof:
- 2. The method according to claim 1, wherein said method further comprises the step of measuring the intraocular pressure of said subject before administering the composition.
- 3. The method according to claim 1, further comprising the step of measuring the intraocular pressure of said subject after administering the composition.
- 4. The method according to claim 1, wherein administering said pharmaceutical composition to said subject is to treat ocular hypertension.
- 5. The method according to claim 4, wherein administering said pharmaceutical composition to said subject is to treat glaucoma.
- 6. The method according claim 1, wherein said pharmaceutical composition is co-administered to said subject with other therapeutic agent or adjuvant therapy commonly used to reduce intraocular pressure.
- 7. The method according to claim 1, wherein at least one of B or B′ is an adenine.
- 8. The method according to claim 1, wherein said compound is a compound of Formula Ia:
- 9. The method according to claim 8, wherein D═O, B═B′=adenine, R1, R2, R3, and R4 are independently H or CR5R6R7, wherein R5═R6═H, and R7=alkyl or arylakyl, provided at least one of Y, Y′, Z, and Z′ equals to OCR5R6R7.
- 10. The method according to claim 9, wherein said compound is selected from the group consisting of di-5′-[(2′-O-benzyl)adenosine] tetraphosphate, di-5′-[(3′-O-benzyl)adenosine] tetraphosphate, di-5′-[(2′,3′-di-O-benzyl)adenosine] tetraphosphate, di-5′-[(2′-O-phenylethyl)adenosine] tetraphosphate, di-5′-[(3′-O-phenylethyl)adenosine] tetraphosphate, and di-5′-[(2′,3′-di-O-phenylethyl)adenosine] tetraphosphate.
- 11. The method according to claim 9, wherein said compound is selected from the group consisting of P1-5′-(2′-O-benzyl)adenosine-P4-5″-adenosine tetraphosphate, P1-5′-(3′-O-benzyl)adenosine-P4-5″-adenosine tetraphosphate, P1-5′-(2′-O-benzyl)adenosine-P4-5″-(3″-O-benzyl)adenosine tetraphosphate, P1-5′-(2′-O-phenylethyl)adenosine-P4-5″-adenosine tetraphosphate, P1-5′-(3′-O-phenylethyl)adenosine-P4-5″-adenosine tetraphosphate, and P1-5′-(2′-O-phenylethyl)adenosine-P4-5″-(3″-O-phenylethyl)adenosine tetraphosphate.
- 12. The method according to claim 8, wherein D═O, B═B′=adenine, R1, R2, R3, and R4 are independently H or CR5R6R7, wherein R5 and R6 are taken together as oxygen, and R7=alkyl or arylakyl, provided at least one of Y, Y′, Z, and Z′ equals to OCR5R6R7.
- 13. The method according to claim 12, wherein said compound is selected from the group consisting of di-5′-[(2′-O-benzoyl)adenosine] tetraphosphate, di-5′-[(3′-O-benzoyl)adenosine]tetraphosphate, di-5′-[(2′,3′-di-O-benzoyl)adenosine] tetraphosphate, di-5′-[(2′-O-phenylacetyl)adenosine] tetraphosphate, di-5′-[(3′-O-phenylacetyl)adenosine] tetraphosphate, and di-5′-[(2′,3′-di-O-phenylacetyl)adenosine] tetraphosphate.
- 14. The method according to claim 12, wherein said compound is selected from the group consisting of P1-5′-(2′-O-benzoyl)adenosine-P4-5″-adenosine tetraphosphate, P1-5′-(3′-O-benzoyl)adenosine-P4-5″-adenosine tetraphosphate, P1-5′-(2′-O-benzoyl)adenosine-P4-5″-(3″-O-benzoyl)adenosine tetraphosphate, P1-5′-(2′-O-phenylacetyl)adenosine-P4-5″-adenosine tetraphosphate, P1-5′-(3′-O-phenylacetyl)adenosine-P4-5″-adenosine tetraphosphate, and P1-5′-(2′-O-phenylacetyl)adenosine-P4-5″-(3″-O-phenylacetyl)adenosine tetraphosphate.
- 15. The method according to claim 1, wherein said compound is a compound of Formula Ib:
- 16. The method according to claim 15, wherein D1═O, B′=adenine, R3═R4=alkyl or arylakyl, provided at least one of Y′ and Z′ equals to OR3 or OR4.
- 17. The method according to claim 16, wherein said compound is selected from the group consisting of 5′-(2′-O-benzyl)adenosine triphosphate, 5′-(3′-O-benzyl)adenosine triphosphate, 5′-(2′,3′-di-O-benzyl)adenosine triphosphate, 5′-(2′-O-phenylethyl)adenosine triphosphate, 5′-(3′-O-phenylethyl)adenosine triphosphate, and 5′-(2′,3′-di-O-phenylethyl)adenosine triphosphate.
- 18. The method according to claim 15, wherein D═O, B═B′=adenine, R3 and R4 are independently H or CR5R6R7, provided at least one of Y′ and Z′ equals to OCR5R6R7, wherein R5 and R6 are taken together as oxygen, and R7=alkyl or arylakyl.
- 19. The method according to claim 18, wherein said compound is selected from the group consisting of 5′-(2′-O-benzoyl)adenosine triphosphate, 5′-(3′-O-benzoyl)adenosine triphosphate, 5′-(2′,3′-di-O-benzoyl)adenosine triphosphate, 5′-(2′-O-phenylacetyl)adenosine triphosphate, 5′-(3′-O-phenylacetyl)adenosine triphosphate, and 5′-(2′,3′-di-O-phenylacetyl)adenosine triphosphate.
- 20. The method according to claim 1, wherein said compound is a compound of Formula Ic, or a pharmaceutically-acceptable salt thereof:
- 21. The method according to claim 20, wherein L1═L2═L3═L4═L5═L6═L7═L8═H.
- 22. The method according to claim 1, wherein said compound is a compound of Formula Id, or a pharmaceutically-acceptable salt thereof, or a 2′-ester or ether thereof, or 3′-ester or ether thereof:
- 23. The method according to claim 22, wherein L1═L2═L3═L4═L5═L6═L7═H.
- 24. The method according to claim 1, wherein said compound is a compound of Formula Ie, or a pharmaceutically-acceptable salt thereof:
- 25. The method according to claim 24, wherein L1═L2═L3═L4═H.
- 26. The method according to claim 1, wherein said pharmaceutical composition is administered topically to said subject.
- 27. The method according to claim 1, wherein said pharmaceutical composition is administered via subconjunctival, subscleral, or intravitreal injection to said subject.
METHOD FOR REDUCING INTRAOCULAR PRESSURE
[0001] This application claims the benefit of U.S. Provisional Application No. 60/350,742, filed Jan. 18, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60350742 |
Jan 2002 |
US |